These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 20622484

  • 1. [Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
    Hagihara M, Kanamori H, Sakai M, Mori T, Nakaseko C, Aotsuka N, Uehara T, Sakura T, Yoshiba F, Kawai N, Tanaka M, Fujisawa S, Ohwada C, Wakita H, Yokota A, Kawamura T, Maruta A, Sakamaki H, Okamoto S, Kanto Study Group for Cell Therapy (KSGCT).
    Rinsho Ketsueki; 2010 Jun; 51(6):390-7. PubMed ID: 20622484
    [Abstract] [Full Text] [Related]

  • 2. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
    Ladenstein R, Peters C, Minkov M, Emminger-Schmidmeier W, Mann G, Höcker P, Hawliczek R, Rosenmayr A, Fink FM, Niederwieser D, Gadner H.
    Klin Padiatr; 1997 Jun; 209(4):201-8. PubMed ID: 9293451
    [Abstract] [Full Text] [Related]

  • 3. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F, Lang PJ, Ottinger H, Faul C, Bethge W, Handgretinger R, Bamberg M, Belka C.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):523-8. PubMed ID: 17869449
    [Abstract] [Full Text] [Related]

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 01; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 5. The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Acquired Severe Aplastic Anemia.
    Lee JW, Cho BS, Lee SE, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Min WS, Park CW.
    Biol Blood Marrow Transplant; 2011 Jan 01; 17(1):101-8. PubMed ID: 20601037
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y, Suzuki R, Kuwatsuka Y, Yasuda T, Takahashi T, Tsujimura A, Sugimoto K, Oba T, Terakura S, Atsuta Y, Murata M, Ito M, Kodera Y, Miyamura K.
    Biol Blood Marrow Transplant; 2008 Jan 01; 14(1):43-9. PubMed ID: 18158960
    [Abstract] [Full Text] [Related]

  • 7. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
    Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF.
    Bone Marrow Transplant; 2007 Sep 01; 40(5):431-5. PubMed ID: 17603511
    [Abstract] [Full Text] [Related]

  • 8. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.
    Biol Blood Marrow Transplant; 2001 Sep 01; 7(11):604-12. PubMed ID: 11760148
    [Abstract] [Full Text] [Related]

  • 9. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
    Min CK, Kim DW, Lee JW, Han CW, Min WS, Kim CC.
    Haematologica; 2001 Mar 01; 86(3):303-10. PubMed ID: 11255278
    [Abstract] [Full Text] [Related]

  • 10. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JL, Silver SM, Braun T, Yanik G, Hutchinson R, Ratanatharathorn V.
    Biol Blood Marrow Transplant; 2003 Mar 01; 9(3):189-97. PubMed ID: 12652470
    [Abstract] [Full Text] [Related]

  • 11. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E, Koza V, Vítek A, Mayer J, Sedlácek P, Zák P, Zapletalová J, Benesová K, Krejcová H, Steinerová K, Maresová I, Cetkovský P.
    Vnitr Lek; 2006 Dec 01; 52(12):1172-80. PubMed ID: 17299910
    [Abstract] [Full Text] [Related]

  • 12. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K.
    Bone Marrow Transplant; 2001 Sep 01; 28(6):557-62. PubMed ID: 11607768
    [Abstract] [Full Text] [Related]

  • 13. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M, Theuser C, Soucek S, Hölig K, Klingebiel T, Blau W, Fauser A, Runde V, Schwinger W, Rutt C, Ehninger G.
    Haematologica; 2000 Aug 01; 85(8):839-47. PubMed ID: 10942931
    [Abstract] [Full Text] [Related]

  • 14. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct 01; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

  • 15. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
    Kim HJ, Park CY, Park YH, Kim YJ, Kim DW, Min WS, Kim CC.
    Bone Marrow Transplant; 2003 Jan 01; 31(2):79-86. PubMed ID: 12621487
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 01; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 17. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
    Martino R, Caballero MD, de la Serna J, Díez-Martín JL, Urbano-Ispízua A, Tomás JF, Odriozola J, León A, Canals C, San Miguel J, Sierra J.
    Bone Marrow Transplant; 2002 Jul 01; 30(2):63-8. PubMed ID: 12132043
    [Abstract] [Full Text] [Related]

  • 18. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R, Enczmann J, Balzer S, Bernbeck B, Kramm C, Schönberger S, Sinha K, Tröger A, Wernet P, Göbel U, Laws HJ, Dilloo D.
    Klin Padiatr; 2005 Jul 01; 217(3):135-41. PubMed ID: 15858704
    [Abstract] [Full Text] [Related]

  • 19. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, Bregante S, Raiola AM, di Grazia C, Dominietto A, Tedone E, Piaggio G, Podesta M, Bruno B, Oneto R, Lombardi A, Frassoni F, Rolla D, Rollandi G, Viscoli C, Ferro C, Garbarino L, Van Lint MT.
    Haematologica; 2004 Oct 01; 89(10):1238-47. PubMed ID: 15477210
    [Abstract] [Full Text] [Related]

  • 20. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2008 May 01; 14(5):568-75. PubMed ID: 18410899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.